Healthcare provider profile · identity verified

Mehak Akhter, MD

Internal Medicine · MESA, AZ · NPI 1720609852

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	266	105
Levothyroxine Sodium	Levothyroxine Sodium	203	80
Rosuvastatin Calcium	Rosuvastatin Calcium	154	69
Lisinopril	Lisinopril	148	60
Amlodipine Besylate	Amlodipine Besylate	130	54
Pantoprazole Sodium	Pantoprazole Sodium	121	59
Losartan Potassium	Losartan Potassium	117	47
Metoprolol Succinate	Metoprolol Succinate	102	39
Gabapentin	Gabapentin	93	39
Metformin Hcl	Metformin Hcl	93	36
Simvastatin	Simvastatin	88	33
Albuterol Sulfate Hfa	Albuterol Sulfate	81	47
Tamsulosin Hcl	Tamsulosin Hcl	77	30
Omeprazole	Omeprazole	75	27
Synthroid	Levothyroxine Sodium	68	28
Hydrochlorothiazide	Hydrochlorothiazide	66	28
Trazodone Hcl	Trazodone Hcl	62	29
Tizanidine Hcl	Tizanidine Hcl	56	44
Alendronate Sodium	Alendronate Sodium	51	18
Metoprolol Tartrate	Metoprolol Tartrate	51	22
Fluticasone Propionate	Fluticasone Propionate	50	33
Diclofenac Sodium	Diclofenac Sodium	44	28
Escitalopram Oxalate	Escitalopram Oxalate	40	17
Pravastatin Sodium	Pravastatin Sodium	39	14
Sertraline Hcl	Sertraline Hcl	39	18
Glipizide	Glipizide	36	15
Doxycycline Hyclate	Doxycycline Hyclate	35	34
Furosemide	Furosemide	35	18
Metformin Hcl Er	Metformin Hcl	35	17
Eliquis	Apixaban	32	17
Finasteride	Finasteride	31	13
Montelukast Sodium	Montelukast Sodium	31	11
Methylprednisolone	Methylprednisolone	30	28
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	29	29
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	27
Shingrix	Varicella-Zoster Ge/As01b/Pf	27	21
Warfarin Sodium	Warfarin Sodium	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Atenolol	Atenolol	24	11
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Ozempic	Semaglutide	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	20
Allopurinol	Allopurinol	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	19	19
Azithromycin	Azithromycin	19	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Jardiance	Empagliflozin	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	11
Prednisone	Prednisone	16	16
Pregabalin	Pregabalin	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	15
Verapamil Er	Verapamil Hcl	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Nadolol	Nadolol	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	13
Potassium Chloride	Potassium Chloride	14	suppressed
Cephalexin	Cephalexin	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	11
Valsartan	Valsartan	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Erythromycin	Erythromycin Base	11	11
Lovastatin	Lovastatin	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error